The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran

Journal of Neuroimmunology

Volumn 250, Issue 1-2, 2012, Pages 87-93

  Rafatpanah, Houshang ^a   Rezaee, Abdolrahim ^a   Etemadi, Mohammad Mehdi ^b   Hosseini, Reza Farid ^a   Khorram, Bita ^c   Afsahr, Leila ^b   Taylor, Graham ^d   Mokhber, Naghmeh ^a   Mahmoudi, Mahmoud ^a   Abbaszadegan, Mohammad Reza ^e   Foroghipor, Mohsen ^b   Hashemi, Peyman ^b   Amiri, Amin ^b   Tehrani, Mohsen ^f   Azarpazhooh, Amir ^g   Azarpazhooh, Mahmoud Reza ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Human T lymphotropic virus type 1; Human T lymphotropic virus type I associated myelopathy tropical spastic paraparesis; Interferon alpha

Indexed keywords

ALPHA2B INTERFERON; CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; HUMAN T CELL LEUKEMIA VIRUS 1 ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; IMMUNOLOGY; IRAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MUSCLE STRENGTH; NEUROLOGIC EXAMINATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RESPONSE TIME; SPASTICITY; TREATMENT DURATION; TROPICAL SPASTIC PARAPARESIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT FUNCTION; VIRUS LOAD;

ADULT; FEMALE; FLOW CYTOMETRY; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; IRAN; MALE; PARAPARESIS, TROPICAL SPASTIC; RECOVERY OF FUNCTION; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84864853401     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.05.004     Document Type: Article

References (34)

1. Arimura K., Nakagawa M., Izumo S., Usuku K., Itoyama Y., Kira J., Osame M. Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. J. Neurovirol. 2007, 13(4):364-372. Available from: PM: 17849320.
2. Blattner W.A., Kalyanaraman V.S., Robert-Guroff M., Lister T.A., Galton D.A., Sarin P.S., Crawford M.H., Catovsky D., Greaves M., Gallo R.C. The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int. J. Cancer 1982, 30(3):257-264. Available from: PM: 6290401.
3. Blattner W.A., Blayney D.W., Robert-Guroff M., Sarngadharan M.G., Kalyanaraman V.S., Sarin P.S., Jaffe E.S., Gallo R.C. Epidemiology of human T-cell leukemia/lymphoma virus. J. Infect. Dis. 1983, 147(3):406-416. Available from: PM: 6300254.
4. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 1987, 67(2):206-207. Available from: PM: 3809245.
5. de The G., Bomford R. An HTLV-I vaccine: why, how, for whom?. AIDS Res. Hum. Retroviruses 1993, 9(5):381-386. Available from: PM: 8318266.
6. Feng J., Misu T., Fujihara K., Saito H., Takahashi T., Kohnosu T., Shiga Y., Takeda A., Sato S., Takase S., Itoyama Y. Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP. J. Neuroimmunol. 2003, 141(1-2):170-173. Available from: PM: 12965269.
7. Feng J., Misu T., Fujihara K., Misawa N., Koyanagi Y., Shiga Y., Takeda A., Sato S., Takase S., Kohnosu T., Saito H., Itoyama Y. Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-alpha. J. Neuroimmunol. 2004, 151(1-2):189-194. Available from: PM: 15145617.
8. Gazzola P., Cocito L., De M.A., Gabutti G., Mancardi G.L. Successful 2-year therapy with systemic interferon-alpha for HTLV-I associated myelopathy. J. Neurol. Sci. 1999, 162(2):205-207. Available from: PM: 10202989.
9. Gessain A., Barin F., Vernant J.C., Gout O., Maurs L., Calender A., de The G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2(8452):407-410. Available from: PM: 2863442.
10. Hinuma Y., Komoda H., Chosa T., Kondo T., Kohakura M., Takenaka T., Kikuchi M., Ichimaru M., Yunoki K., Sato I., Matsuo R., Takiuchi Y., Uchino H., Hanaoka M. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int. J. Cancer 1982, 29(6):631-635. Available from: PM: 6980846.
11. Izumo S., Usuku K., Osame M., Arimura K., Igata A. Effect of alpha-interferon treatment on HTLV-1 associated myelopathy (HAM). Neurology 1988, (39):242.
12. Izumo S., Goto I., Itoyama Y., Okajima T., Watanabe S., Kuroda Y., Araki S., Mori M., Nagataki S., Matsukura S., Akamine T., Nakagawa M., Yamamoto I., Osame M. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996, 46(4):1016-1021. Available from: PM: 8780082.
13. Katsoulidou A., Papachristou E., Petrodaskalaki M., Sypsa V., Anastassopoulou C.G., Gargalianos P., Karafoulidou A., Lazanas M., Kordossis T., Andoniadou A., Hatzakis A. Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Virol. Methods 2004, 121(1):93-99. Available from: PM: 15350738.
14. Kchour G., Makhoul N.J., Mahmoudi M., Kooshyar M.M., Shirdel A., Rastin M., Rafatpanah H., Tarhini M., Zalloua P.A., Hermine O., Farid R., Bazarbachi A. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk. Lymphoma 2007, 48(2):330-336. Available from: PM: 17325893.
15. Maloney E.M., Ramirez H., Levin A., Blattner W.A. A survey of the human T-cell lymphotropic virus type I (HTLV-I) in south-western Colombia. Int. J. Cancer 1989, 44(3):419-423. Available from: PM: 2777408.
16. Matsuo H., Nakamura T., Tsujihata M., Kinoshita I., Satoh A., Tomita I., Shirabe S., Shibayama K., Nagataki S. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 1988, 2(8620):1109-1113. Available from: PM: 2903326.
17. Nakagawa M., Nakahara K., Maruyama Y., Kawabata M., Higuchi I., Kubota H., Izumo S., Arimura K., Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 1996, 2(5):345-355. Available from: PM: 8912211.
18. Nakamura T., Shibayama K., Nagasato K., Matsuo H., Tsujihata M., Nagataki S. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy. Jpn. J. Med. 1990, 29(4):362-367. Available from: PM: 2273619.
19. Osame M. Review of WHO Kagoshima Meeting and Diagnostic Guidelines for HAM/TSP 1990, Raven Press, New York.
20. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1(8488):1031-1032. Available from: PM: 2871307.
21. Osame M., Igata A., Matsumoto M., Kohka M., Usuku K., Izumo S. HTLV-1-associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings. Hematol. Rev. 1990, 3:271-284.
22. Rafatpanah H., Pravica V., Faridhosseini R., Tabatabaei A., Ollier W., Poulton K., Thomson W., Hutchinson I. Association between HLA-DRB1*01 and HLA-Cw*08 and outcome following HTLV-I infection. Iran J. Immunol. 2007, 4(2):94-100. Available from: PM: 1765284.
23. Rafatpanah H., Hedayati-Moghaddam M.R., Fathimoghadam F., Bidkhori H.R., Shamsian S.K., Ahmadi S., Sohgandi L., Azarpazhooh M.R., Rezaee S.A., Farid R., Bazarbachi A. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J. Clin. Virol. 2011, Available from: PM: 21840754.
24. Reeves W.C., Saxinger C., Brenes M.M., Quiroz E., Clark J.W., Hoh M.W., Blattner W.A. Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology and risk factors in metropolitan Panama. Am. J. Epidemiol. 1988, 127(3):532-539. Available from: PM: 2893539.
25. Sabouri A.H., Saito M., Usuku K., Bajestan S.N., Mahmoudi M., Forughipour M., Sabouri Z., Abbaspour Z., Goharjoo M.E., Khayami E., Hasani A., Izumo S., Arimura K., Farid R., Osame M. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J. Gen. Virol. 2005, 86(Pt 3):773-781. Available from: PM: 15722539.
26. Saito M., Nakagawa M., Kaseda S., Matsuzaki T., Jonosono M., Eiraku N., Kubota R., Takenouchi N., Nagai M., Furukawa Y., Usuku K., Izumo S., Osame M. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 2004, 189(1):29-40. Available from: PM: 14702150.
27. Saito M., Nose H., Usuku K., Sabouri A.H., Matsuzaki T., Izumo S., Arimura K., Osame M. Flow cytometry evaluation of the T-cell receptor V beta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J. Neurol. Sci. 2006, 246(1-2):37-43. Available from: PM: 16545396.
28. Saxinger W., Blattner W.A., Levine P.H., Clark J., Biggar R., Hoh M., Moghissi J., Jacobs P., Wilson L., Jacobson R. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. Science 1984, 225(4669):1473-1476. Available from: PM: 6089348.
29. Schmitt Y. Performance characteristics of quantification assays for human immunodeficiency virus type 1 RNA. J. Clin. Virol. 2001, 20(1-2):31-33. Available from: PM: 11163580.
30. Sheremata W.A., Benedict D., Squilacote D.C., Sazant A., DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 1993, 43(10):2125-2129. Available from: PM: 8413977.
31. Shibayama K., Nakamura T., Nagasato K., Shirabe S., Tsujihata M., Nagataki S. Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects. J. Neurol. Sci. 1991, 106(2):186-192. Available from: PM: 1802967.
32. Tamura K., Makino S., Araki Y., Imamura T., Seita M. Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 1987, 59(6):1059-1062. Available from: PM: 2880655.
33. Taylor G.P., Goon P., Furukawa Y., Green H., Barfield A., Mosley A., Nose H., Babiker A., Rudge P., Usuku K., Osame M., Bangham C.R., Weber J.N. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006, 3:63. Available from: PM: 16984654.
34. Yamasaki K., Kira J., Koyanagi Y., Kawano Y., Miyano-Kurosaki N., Nakamura M., Baba E., Suzuki J., Yamamoto A., Yamamoto N., Kobayashi T. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J. Neurol. Sci. 1997, 147(2):135-144. Available from: PM: 9106118.